BlackOp Stocks

[Pennybuster]

$BSSP Valuation to Consider


Via Sterling

I must say first that I believe that the initial thoughts were correct with assessing the Stage 3 clinical trials in Europe to be for the therapy to treat HIV at a hospital in Bulgaria. It is known that it was a Bulgarian Hospital that gave Dr. Zhabilov $2 million USD so the Irreversible Pepsin Fraction (IPF) therapy for HIV could get approved in Europe (EU). Although BSSP/Canteck Pharma, Inc. did not mention such within their recent PR and only mentioned that they have current and planned operations in Mexico through the exclusive Sub Licensing Agreement for IPF specific to the Cancer, there is some serious research that confirms your initial research on the matter within the slideshow below:
http://www.cantechpharma.com/wp-content/uploads/2016/02/Cantech-IPF.pdf


Now let’s justify a BSSP valuation of which I believe is very fair and conservative. Within the recent 8-K that BSSP filed with the SEC, they stated that the Authorized Shares (AS) was 5,000,000,000 Shares:
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/0001594062-16-000450-index.htm
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/form8k.htm

So, as a worst case scenario, let’s presume that the Outstanding Shares (OS) for BSSP is maxed out to be the 5,000,000,000 shares.

Although I think the potential is far greater, let’s now presume that BSSP is a $20,000,000 company as some have conservatively stated.

I think everyone here can agree that BSSP/Canteck Pharma, Inc. would exist to trade within the Healthcare Sector and within the Industry titled Drug Manufacturers – Other. Within the link below, you will see that the current Price to Earnings (P/E) Ratio is 27.90 and the current Net Profit Margin is 18.5%:

https://biz.yahoo.com/p/5conameu.html


Now that we have some Key Fundamental Variables, we can assess a Fundamental Valuation for where BSSP could logically trade upon the consummation of BSSP completing the One Hundred Percent (100%) ownership Interest in Canteck Pharma, Inc. for its current and planned operations in Mexico:
http://finance.yahoo.com/news/reve-acquires-exclusive-license-cantecks-133000687.html

Key Fundamental Variables
** Net Income = $20,000,000 Revenues x .185 Net Profit Margin = $3,700,000 Net Income
** OS = 5,000,000,000 Shares
** P/E Ratio for Technology Sector = 27.90
** Net Income ÷ OS = EPS
** EPS x P/E Ratio = Per Share Valuation

$3,700,000 Net Income ÷ 5,000,000,000 (OS) = .00074 EPS

.00074 EPS x 27.90 P/E Ratio = .0206 Per Share Valuation

I hope one would see that the above .0206 Per Share Valuation for BSSP that was derived through logical deduction from the given variables above is fair to consider if this deal closes.

I think too it is important for one to use the Substitution Property for any of the variables that would change as more details are ”officially” released from the company through their PRs and their SEC filings. So, as a worst case scenario from the variables above, BSSP is significantly undervalued here at these levels if this deal with Canteck Pharma, Inc. closes. This is why I believe, in my opinion, it’s just a matter of time before the rest of the market or enough of the market realizes such.



http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122284786